EVER PHARMA

STROKE
TBI
DEMENTIA

# SMALL MOMENT. BIG DIFFERENCE.

Last month Catherine had a TBI.
**Today she enjoys life again.**


**Cerebrolysin®**
Reconnecting Neurons.
Empowering for Life.

**Quality from Austria.**

EVER PHARMA

Cerebrolysin®
Reconnecting Neurons.
Empowering for Life.

# Big Problem with depression after TBI – What to do?

About half of TBI patients are affected by depression within the first year after injury and even nearly two-thirds within seven years.[1]


## Treatment of such consequences is essential!

# Having fun in life again!

- Reduce the burden of depression after TBI
- Faster reintegration into social life
- Superior quality of life

**CEREBROLYSIN®**
HADS depression




*Figure: HADS depression sumscore, MW, Day 90, PP*

*Large inferiority = 0,29; Medium inferiority = 0,36, Small inferiority = 0,44; Equality = 0,50; Small superiority = 0,56; Medium superiority = 0,64; Large superiority = 0,71*

- Cerebrolysin® shows **large-sized superiority** on day 90
- HADS Depression sumscore shows already **stand alone significance on day 30**

# Treat TBI patients with Cerebrolysin® as soon as possible!

## The effective treatment after TBI

- Early treatment effects
- Significantly reduced depression
- Improvement of memory and concentration

| Disorder | Daily dosage | Initiation of treatment | Duration of treatment |
|---|---|---|---|
| Traumatic brain injury | 20 - 50 ml | as soon as possible | 7 - 30 days |

**Title:** Efficacy and safety of Cerebrolysin® in Neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial

**Patients:** 80 Cerebrolysin® group + 59 Placebo group = 139 patient in total

**Treatment:** Treatment Cycle 1 = Day 1 - 10 : 50 ml/day
Treatment Cycle 2 = Day 31 - 40 : 10 ml/day
Treatment Cycle 3 = Day 61 - 70 : 10 ml/day

1 Fann, Jesse R., Tessa Hart, and Katherine G. Schomer. "Treatment for depression after traumatic brain injury: a systematic review." Journal of neurotrauma 26.12 (2009): 2383-2402)
2 Comparative Effectiveness Review Summary Guides for Consumers, Rockville (MD): Agency for Healthcare Research and Quality (US); 2005
3 Muresanu, Dafin F., et al. "Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial." Neurological Sciences (2020): 1-11


ABBREVIATED PRESCRIBING INFORMATION - Cerebrolysin. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics. (Reference SPC – CCDS Version 2.0/03.06.2016)
EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria, www.everpharma.com, www.cerebrolysin.com

CERE/INT/01/2020/4